403 related articles for article (PubMed ID: 32350398)
1. Progress in refining the clinical management of cancer of unknown primary in the molecular era.
Rassy E; Pavlidis N
Nat Rev Clin Oncol; 2020 Sep; 17(9):541-554. PubMed ID: 32350398
[TBL] [Abstract][Full Text] [Related]
2. Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?
Olivier T; Fernandez E; Labidi-Galy I; Dietrich PY; Rodriguez-Bravo V; Baciarello G; Fizazi K; Patrikidou A
Cancer Treat Rev; 2021 Jun; 97():102204. PubMed ID: 33866225
[TBL] [Abstract][Full Text] [Related]
3. Cancer of Unknown Primary in the Molecular Era.
Kato S; Alsafar A; Walavalkar V; Hainsworth J; Kurzrock R
Trends Cancer; 2021 May; 7(5):465-477. PubMed ID: 33516660
[TBL] [Abstract][Full Text] [Related]
4. Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.
Hayashi H; Kurata T; Takiguchi Y; Arai M; Takeda K; Akiyoshi K; Matsumoto K; Onoe T; Mukai H; Matsubara N; Minami H; Toyoda M; Onozawa Y; Ono A; Fujita Y; Sakai K; Koh Y; Takeuchi A; Ohashi Y; Nishio K; Nakagawa K
J Clin Oncol; 2019 Mar; 37(7):570-579. PubMed ID: 30653423
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic challenges of patients with carcinoma of unknown primary.
Rassy E; Pavlidis N
Expert Rev Anticancer Ther; 2020 Sep; 20(9):775-783. PubMed ID: 32779501
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.
Ross JS; Wang K; Gay L; Otto GA; White E; Iwanik K; Palmer G; Yelensky R; Lipson DM; Chmielecki J; Erlich RL; Rankin AN; Ali SM; Elvin JA; Morosini D; Miller VA; Stephens PJ
JAMA Oncol; 2015 Apr; 1(1):40-49. PubMed ID: 26182302
[TBL] [Abstract][Full Text] [Related]
7. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review.
Pentheroudakis G; Greco FA; Pavlidis N
Cancer Treat Rev; 2009 May; 35(3):221-7. PubMed ID: 19046817
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the 'U' out of 'CUP'.
Conway AM; Mitchell C; Kilgour E; Brady G; Dive C; Cook N
Br J Cancer; 2019 Jan; 120(2):141-153. PubMed ID: 30580378
[TBL] [Abstract][Full Text] [Related]
9. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
Hainsworth JD; Rubin MS; Spigel DR; Boccia RV; Raby S; Quinn R; Greco FA
J Clin Oncol; 2013 Jan; 31(2):217-23. PubMed ID: 23032625
[TBL] [Abstract][Full Text] [Related]
10. CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence.
Zhao Y; Pan Z; Namburi S; Pattison A; Posner A; Balachander S; Paisie CA; Reddi HV; Rueter J; Gill AJ; Fox S; Raghav KPS; Flynn WF; Tothill RW; Li S; Karuturi RKM; George J
EBioMedicine; 2020 Nov; 61():103030. PubMed ID: 33039710
[TBL] [Abstract][Full Text] [Related]
11. The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary
Dermawan JK; Rubin BP
Semin Diagn Pathol; 2021 Nov; 38(6):193-198. PubMed ID: 33309276
[TBL] [Abstract][Full Text] [Related]
12. Cancer of Unknown Primary origin in the genomic era: Elucidating the dark box of cancer.
Economopoulou P; Mountzios G; Pavlidis N; Pentheroudakis G
Cancer Treat Rev; 2015 Jul; 41(7):598-604. PubMed ID: 26033502
[TBL] [Abstract][Full Text] [Related]
13. A Review on Cancer of Unknown Primary Origin: The Role of Molecular Biomarkers in the Identification of Unknown Primary Origin.
Yan N; Zhang Y; Guo X; Yuan D; Tian G; Yang J
Methods Mol Biol; 2020; 2204():109-119. PubMed ID: 32710319
[TBL] [Abstract][Full Text] [Related]
14. The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review.
Lorkowski SW; Dermawan JK; Rubin BP
Virchows Arch; 2024 Feb; 484(2):369-375. PubMed ID: 37999736
[TBL] [Abstract][Full Text] [Related]
15. Overview of various techniques/platforms with critical evaluation of each.
Agwa E; Ma PC
Curr Treat Options Oncol; 2013 Dec; 14(4):623-33. PubMed ID: 24243164
[TBL] [Abstract][Full Text] [Related]
16. New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: progress and challenges.
Ma W; Wu H; Chen Y; Xu H; Jiang J; Du B; Wan M; Ma X; Chen X; Lin L; Su X; Bao X; Shen Y; Xu N; Ruan J; Jiang H; Ding Y
Brief Bioinform; 2024 Jan; 25(2):. PubMed ID: 38343328
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies.
Zaun G; Borchert S; Metzenmacher M; Lueong S; Wiesweg M; Zaun Y; Pogorzelski M; Behrens F; Schildhaus HU; Virchow I; Kasper S; Schuler M; Theurer S; Liffers S
Eur J Cancer; 2024 Mar; 200():113540. PubMed ID: 38316065
[TBL] [Abstract][Full Text] [Related]
18. Perspectives for targeted therapies in cancer of unknown primary site.
Pentheroudakis G; Pavlidis N
Cancer Treat Rev; 2006 Dec; 32(8):637-44. PubMed ID: 17046164
[TBL] [Abstract][Full Text] [Related]
19. Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management.
Greco FA
Curr Treat Options Oncol; 2013 Dec; 14(4):634-42. PubMed ID: 23990214
[TBL] [Abstract][Full Text] [Related]
20. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]